Aromatic diamidines as antiparasitic agents

M. N.C. Soeiro, E. M. De Souza, Chad E. Stephens, D. W. Boykin

Research output: Contribution to journalReview article

89 Citations (Scopus)

Abstract

Parasitic infections are widespread in developing countries and frequently associated with immunocompromised patients in developed countries. Consequently, such infections are responsible for a significant amount of human mortality, morbidity and economic hardship. A growing consensus has identified the urgent need for the development of new antiparasitic compounds, mostly due to the large number of drug-resistant parasites and the fact that currently available drugs are expensive, highly toxic, require long treatment regimens and frequently exhibit significantly reduced activity towards certain parasite strains and evolutive stages. In this context, the activity of aromatic diamidines has been explored against a widespread range of microorganisms, and the authors' present aim is to review the current status of chemotherapy with these compounds against human parasitic infections.

Original languageEnglish (US)
Pages (from-to)957-972
Number of pages16
JournalExpert Opinion on Investigational Drugs
Volume14
Issue number8
DOIs
StatePublished - Aug 1 2005

Fingerprint

Pentamidine
Antiparasitic Agents
Parasitic Diseases
Parasites
Poisons
Immunocompromised Host
Developed Countries
Pharmaceutical Preparations
Developing Countries
Economics
Morbidity
Drug Therapy
Mortality
Infection
Therapeutics

Keywords

  • Aromatic diamidines
  • Chaga's disease
  • Chemotherapy
  • Leishmania
  • Malaria
  • Parasites
  • Trypanosomes

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Aromatic diamidines as antiparasitic agents. / Soeiro, M. N.C.; De Souza, E. M.; Stephens, Chad E.; Boykin, D. W.

In: Expert Opinion on Investigational Drugs, Vol. 14, No. 8, 01.08.2005, p. 957-972.

Research output: Contribution to journalReview article

Soeiro, M. N.C. ; De Souza, E. M. ; Stephens, Chad E. ; Boykin, D. W. / Aromatic diamidines as antiparasitic agents. In: Expert Opinion on Investigational Drugs. 2005 ; Vol. 14, No. 8. pp. 957-972.
@article{792eba85cf474102abd3800ff1e96b85,
title = "Aromatic diamidines as antiparasitic agents",
abstract = "Parasitic infections are widespread in developing countries and frequently associated with immunocompromised patients in developed countries. Consequently, such infections are responsible for a significant amount of human mortality, morbidity and economic hardship. A growing consensus has identified the urgent need for the development of new antiparasitic compounds, mostly due to the large number of drug-resistant parasites and the fact that currently available drugs are expensive, highly toxic, require long treatment regimens and frequently exhibit significantly reduced activity towards certain parasite strains and evolutive stages. In this context, the activity of aromatic diamidines has been explored against a widespread range of microorganisms, and the authors' present aim is to review the current status of chemotherapy with these compounds against human parasitic infections.",
keywords = "Aromatic diamidines, Chaga's disease, Chemotherapy, Leishmania, Malaria, Parasites, Trypanosomes",
author = "Soeiro, {M. N.C.} and {De Souza}, {E. M.} and Stephens, {Chad E.} and Boykin, {D. W.}",
year = "2005",
month = "8",
day = "1",
doi = "10.1517/13543784.14.8.957",
language = "English (US)",
volume = "14",
pages = "957--972",
journal = "Expert Opinion on Investigational Drugs",
issn = "1354-3784",
publisher = "Taylor and Francis Ltd.",
number = "8",

}

TY - JOUR

T1 - Aromatic diamidines as antiparasitic agents

AU - Soeiro, M. N.C.

AU - De Souza, E. M.

AU - Stephens, Chad E.

AU - Boykin, D. W.

PY - 2005/8/1

Y1 - 2005/8/1

N2 - Parasitic infections are widespread in developing countries and frequently associated with immunocompromised patients in developed countries. Consequently, such infections are responsible for a significant amount of human mortality, morbidity and economic hardship. A growing consensus has identified the urgent need for the development of new antiparasitic compounds, mostly due to the large number of drug-resistant parasites and the fact that currently available drugs are expensive, highly toxic, require long treatment regimens and frequently exhibit significantly reduced activity towards certain parasite strains and evolutive stages. In this context, the activity of aromatic diamidines has been explored against a widespread range of microorganisms, and the authors' present aim is to review the current status of chemotherapy with these compounds against human parasitic infections.

AB - Parasitic infections are widespread in developing countries and frequently associated with immunocompromised patients in developed countries. Consequently, such infections are responsible for a significant amount of human mortality, morbidity and economic hardship. A growing consensus has identified the urgent need for the development of new antiparasitic compounds, mostly due to the large number of drug-resistant parasites and the fact that currently available drugs are expensive, highly toxic, require long treatment regimens and frequently exhibit significantly reduced activity towards certain parasite strains and evolutive stages. In this context, the activity of aromatic diamidines has been explored against a widespread range of microorganisms, and the authors' present aim is to review the current status of chemotherapy with these compounds against human parasitic infections.

KW - Aromatic diamidines

KW - Chaga's disease

KW - Chemotherapy

KW - Leishmania

KW - Malaria

KW - Parasites

KW - Trypanosomes

UR - http://www.scopus.com/inward/record.url?scp=23644434124&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23644434124&partnerID=8YFLogxK

U2 - 10.1517/13543784.14.8.957

DO - 10.1517/13543784.14.8.957

M3 - Review article

C2 - 16050790

AN - SCOPUS:23644434124

VL - 14

SP - 957

EP - 972

JO - Expert Opinion on Investigational Drugs

JF - Expert Opinion on Investigational Drugs

SN - 1354-3784

IS - 8

ER -